atezolizumab,Bevacizumab
roche
['bcsm', 'atezo', 'hcc']
time for 1st #asco23 poll. first phase-3 trial in adjuvant hcc setting:
adjuvant atezo bev
78% 65% 12 month rfs rate. for hepatocellular cancer (hcc) #hpbcsm. #asco23 #immunotherapy time to include in guidelines? practice changing? 
Oncologist | Researcher | ColorectalCancer #CRCSM👨🏼‍🎓@MayoClinic @PittTweet Alum; 🧬#ctDNA #LiquidBiopsies💡#PrecisionOncology ViewsMy Own. COI @ASCO📍 #GI23